- Home
- INAB vs SILO Comparison
INAB vs SILO Comparison
Compare INAB & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INAB
- SILO
- Stock Information
- Founded
- INAB 2016
- SILO 2010
- Country
- INAB United States
- SILO United States
- Employees
- INAB N/A
- SILO 3
- Industry
- INAB Biotechnology: Pharmaceutical Preparations
- SILO Apparel
- Sector
- INAB Health Care
- SILO Consumer Discretionary
- Exchange
- INAB Nasdaq
- SILO Nasdaq
- Market Cap
- INAB 7.5M
- SILO 6.3M
- IPO Year
- INAB 2021
- SILO N/A
- Fundamental
- Price
- INAB $2.26
- SILO $0.63
- Analyst Decision
- INAB Strong Buy
- SILO
- Analyst Count
- INAB 2
- SILO 0
- Target Price
- INAB $108.00
- SILO N/A
- AVG Volume (30 Days)
- INAB 92.2K
- SILO 593.7K
- Earning Date
- INAB 08-07-2025
- SILO 08-13-2025
- Dividend Yield
- INAB N/A
- SILO N/A
- EPS Growth
- INAB N/A
- SILO N/A
- EPS
- INAB N/A
- SILO N/A
- Revenue
- INAB N/A
- SILO $72,102.00
- Revenue This Year
- INAB N/A
- SILO $1.86
- Revenue Next Year
- INAB N/A
- SILO N/A
- P/E Ratio
- INAB N/A
- SILO N/A
- Revenue Growth
- INAB N/A
- SILO N/A
- 52 Week Low
- INAB $1.98
- SILO $0.41
- 52 Week High
- INAB $17.64
- SILO $3.37
- Technical
- Relative Strength Index (RSI)
- INAB 47.63
- SILO 45.96
- Support Level
- INAB $2.10
- SILO $0.60
- Resistance Level
- INAB $2.46
- SILO $0.70
- Average True Range (ATR)
- INAB 0.14
- SILO 0.06
- MACD
- INAB 0.02
- SILO -0.01
- Stochastic Oscillator
- INAB 56.12
- SILO 41.76
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.